Orion Oyj (OTCMKTS:ORINY - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $31.10 and last traded at $31.10, with a volume of 706 shares. The stock had previously closed at $30.48.
Analysts Set New Price Targets
Separately, Nordea Equity Research cut Orion Oyj to a "hold" rating in a report on Tuesday, February 4th.
Read Our Latest Stock Analysis on ORINY
Orion Oyj Trading Down 8.7 %
The company has a market cap of $8.01 billion, a price-to-earnings ratio of 22.53 and a beta of 0.15. The company has a quick ratio of 1.41, a current ratio of 2.42 and a debt-to-equity ratio of 0.25. The company's fifty day moving average price is $28.51 and its two-hundred day moving average price is $25.87.
Orion Oyj (OTCMKTS:ORINY - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.28 EPS for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. The company had revenue of $463.41 million for the quarter. Research analysts expect that Orion Oyj will post 1.18 earnings per share for the current year.
Orion Oyj Increases Dividend
The business also recently disclosed a dividend, which will be paid on Tuesday, April 29th. Shareholders of record on Monday, April 7th will be given a $0.4478 dividend. The ex-dividend date of this dividend is Monday, April 7th. This is a boost from Orion Oyj's previous dividend of $0.24. Orion Oyj's dividend payout ratio (DPR) is presently 24.00%.
Orion Oyj Company Profile
(
Get Free Report)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.
Featured Articles
Before you consider Orion Oyj, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orion Oyj wasn't on the list.
While Orion Oyj currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
